Concordia closes Amdipharm Mercury buy, Cinven investment
Concordia Healthcare Corp (NASDAQ: CXRX, TSX: CXR) has completed its purchase of Amdipharm Mercury Ltd, a London, U.K.-based pharmaceutical company. The deal, announced in September, was valued at US$3.3 billion, including debt. The sellers included European private equity firm Cinven, which as a result of the transaction will assume a 14.2 percent investment stake in Concordia. Concordia, which has its headquarters in Oakville, Ontario, said the acquisition has diversified its drug portfolio and increased its size to more than 200 products sold in over 100 countries.
22 October 2015•7 mins read
